PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH

Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65206-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)65206-0/fulltext
Section Title :
Section Order : 365
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65206-0&doi=10.1016/S1098-3015(10)65206-0
HEOR Topics :
Tags :
Regions :